Dacarbazine (DTIC-Dome)

Dacarbazine is an approved anti-cancer drug, which is used frequently in combination with other drugs for the treatment of metastatic melanoma and Hodgkin’s disease.

It comes as powder that is reconstituted into a liquid for intravenous injection. It suppresses the bone marrow, causing leukopenia and thrombocytopenia. Other common side-effects include nausea, vomiting and hair loss.

Dacarbazine is manufactured by Bayer under the tradename DTIC-Dome.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.